# Uxin Ltd: financial statements, quarterly

UXIN · Nasdaq · CIK 1729173 · [Industrials](/sectors/industrials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/uxin.md) · [Financials](/companies/uxin/financials.md) · [Filings](/companies/uxin/filings.md) · [Insiders](/companies/uxin/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/uxin/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2021 (2020-03-31) |
| --- | --- | ---: |
| Revenue | $m | [14.7](/filings/0001104659-20-086426.md) |
| Cost of revenue | $m | [15.6](/filings/0001104659-20-086426.md) |
| Gross profit | $m | [(1.0)](/filings/0001104659-20-086426.md) |
| Research and development | $m | [4.4](/filings/0001104659-20-086426.md) |
| Operating income | $m | [(309)](/filings/0001104659-20-086426.md) |
| Interest expense | $m | [4.1](/filings/0001104659-20-086426.md) |
| Income tax | $m | [0.0](/filings/0001104659-20-086426.md) |
| Net income | $m | [(351)](/filings/0001104659-20-086426.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss

## Balance sheet

| Line item | Unit | FY2018 (2018-12-31) | FY2019 (2019-12-31) | FY2021 (2020-03-31) | FY2021 (2021-03-31) | FY2022 (2022-03-31) | period not labelled (2022-12-31) | FY2023 (2023-03-31) | FY2024 (2024-03-31) | FY2025 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [117](/filings/0001104659-19-024306.md) | [68.5](/filings/0001104659-20-060191.md) | [48.4](/filings/0001104659-20-086426.md) | [29.4](/filings/0001104659-21-098224.md) | [20.2](/filings/0000950170-22-013561.md) | not reported | [13.5](/filings/0000950170-23-042446.md) | [3.2](/filings/0001493152-24-029702.md) | [3.4](/filings/0001641172-25-006780.md) | [11.9](/filings/0001493152-26-020425.md) |
| Current assets | $m | [972](/filings/0001104659-19-024306.md) | [709](/filings/0001104659-20-060191.md) | [316](/filings/0001104659-20-086426.md) | [127](/filings/0001104659-21-098224.md) | [138](/filings/0000950170-22-013561.md) | not reported | [41.0](/filings/0000950170-23-042446.md) | [31.4](/filings/0001493152-24-029702.md) | [46.5](/filings/0001641172-25-006780.md) | [106](/filings/0001493152-26-020425.md) |
| Total assets | $m | [1,071](/filings/0001104659-19-024306.md) | [772](/filings/0001104659-20-060191.md) | [374](/filings/0001104659-20-086426.md) | [188](/filings/0001104659-21-098224.md) | [197](/filings/0000950170-22-013561.md) | not reported | [105](/filings/0000950170-23-042446.md) | [289](/filings/0001493152-24-029702.md) | [267](/filings/0001641172-25-006780.md) | [346](/filings/0001493152-26-020425.md) |
| Current liabilities | $m | [650](/filings/0001104659-19-024306.md) | [429](/filings/0001104659-20-060191.md) | [434](/filings/0001104659-20-086426.md) | [175](/filings/0001104659-21-098224.md) | [205](/filings/0000950170-22-013561.md) | not reported | [87.9](/filings/0000950170-23-042446.md) | [123](/filings/0001493152-24-029702.md) | [104](/filings/0001641172-25-006780.md) | [140](/filings/0001493152-26-020425.md) |
| Total liabilities | $m | [725](/filings/0001104659-19-024306.md) | [705](/filings/0001104659-20-060191.md) | [705](/filings/0001104659-20-086426.md) | [493](/filings/0001104659-21-098224.md) | [353](/filings/0000950170-22-013561.md) | not reported | [189](/filings/0000950170-23-042446.md) | [309](/filings/0001493152-24-029702.md) | [297](/filings/0001641172-25-006780.md) | [331](/filings/0001493152-26-020425.md) |
| Long-term debt | $m | [70.2](/filings/0001104659-19-024306.md) | not reported | not reported | [313](/filings/0000950170-22-013561.md) | [233](/filings/0000950170-22-013561.md) | [233](/filings/0000950170-23-042446.md) | [42.5](/filings/0000950170-23-042446.md) | not reported | [7.4](/filings/0001641172-25-006780.md) | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | [36.8](/filings/0000950170-22-013561.md) | not reported | not reported | [40.4](/filings/0001493152-24-029702.md) | not reported | not reported |
| Short-term borrowings | $m | [91.0](/filings/0001104659-19-024306.md) | not reported | not reported | not reported | not reported | not reported | [2.9](/filings/0000950170-23-042446.md) | not reported | not reported | not reported |
| Shareholders' equity | $m | [346](/filings/0001104659-19-024306.md) | [67.3](/filings/0001104659-20-060191.md) | [(331)](/filings/0001104659-20-086426.md) | [(305)](/filings/0001104659-21-098224.md) | [(238)](/filings/0000950170-22-013561.md) | not reported | [(185)](/filings/0000950170-23-042446.md) | [(40.6)](/filings/0001493152-24-029702.md) | [(50.4)](/filings/0001641172-25-006780.md) | [(33.0)](/filings/0001493152-26-020425.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent, us-gaap:LongTermDebt
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2021 (2020-03-31) |
| --- | --- | ---: |
| Operating cash flow | $m | [(58.1)](/filings/0001104659-20-086426.md) |
| Capital expenditure | $m | [0.0](/filings/0001104659-20-086426.md) |
| Share repurchases | $m | [1.0](/filings/0001104659-20-086426.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q4 FY2021 (2020-03-31) |
| --- | --- | ---: |
| Diluted shares (weighted) | millions of shares | [888](/filings/0000950170-22-013561.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.